151 related articles for article (PubMed ID: 35443723)
1. Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma.
Wang Z; Wang X; Xu Y; Li J; Zhang X; Peng Z; Hu Y; Zhao X; Dong K; Zhang B; Gao C; Zhao X; Chen H; Cai J; Bai Y; Sun Y; Shen L
BMC Med; 2022 Apr; 20(1):133. PubMed ID: 35443723
[TBL] [Abstract][Full Text] [Related]
2. A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
Moreau M; Alouani E; Flecchia C; Falcoz A; Gallois C; Auclin E; André T; Cohen R; Hollebecque A; Turpin A; Pernot S; Masson T; Di Fiore F; Dutherge M; Mazard T; Hautefeuille V; Van Laethem JL; De la Fouchardière C; Perkins G; Ben-Abdelghani M; Sclafani F; Aparicio T; Kim S; Vernerey D; Taieb J; Guimbaud R; Tougeron D
Eur J Cancer; 2024 May; 202():114033. PubMed ID: 38537314
[TBL] [Abstract][Full Text] [Related]
3. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome data-based status of PI3K/AKT/mTOR pathway indicates heterogeneity and immune modulation in patients with pancreatic ductal adenocarcinoma.
Xie P; Tan SY; Li HF; Tang HD; Zhou JH
J Gene Med; 2024 Jan; 26(1):e3570. PubMed ID: 37482968
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer.
Li J; Hu H; Qin G; Bai F; Wu X; Ke H; Zhang J; Xie Y; Wu Z; Fu Y; Zheng H; Gong L; Xie Z; Deng Y
Clin Cancer Res; 2024 Jan; 30(2):368-378. PubMed ID: 37906636
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of FAT1 mutations to indicate the immune response in colorectal cancer patients.
Zhu W; Yang L; Gao Y; Zhou Y; Shi Y; Liu K; Yu R; Shao Y; Zhang W; Wu G; He J
Genomics; 2024 Mar; 116(2):110808. PubMed ID: 38364976
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of MSI Cancer: Facts and Hopes.
Wilbur HC; Le DT; Agarwal P
Clin Cancer Res; 2024 Apr; 30(8):1438-1447. PubMed ID: 38015720
[TBL] [Abstract][Full Text] [Related]
8. Microsatellite instability: A 2024 update.
Yamamoto H; Watanabe Y; Arai H; Umemoto K; Tateishi K; Sunakawa Y
Cancer Sci; 2024 Mar; ():. PubMed ID: 38528657
[TBL] [Abstract][Full Text] [Related]
9. DNA mismatch repair in cancer immunotherapy.
Guan J; Li GM
NAR Cancer; 2023 Sep; 5(3):zcad031. PubMed ID: 37325548
[TBL] [Abstract][Full Text] [Related]
10. The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer.
Klümper N; Grünwald V; Hartmann A; Hölzel M; Eckstein M
Eur Urol; 2024 May; ():. PubMed ID: 38744632
[TBL] [Abstract][Full Text] [Related]
11. RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.
Jiang Y; Hu X; Wang Z; Zhang Q; Chen D; Zhao P
Invest New Drugs; 2024 Feb; 42(1):60-69. PubMed ID: 38071684
[TBL] [Abstract][Full Text] [Related]
12. Cautious optimism-the current role of immunotherapy in gastrointestinal cancers.
Mendis S; Gill S
Curr Oncol; 2020 Apr; 27(Suppl 2):S59-S68. PubMed ID: 32368175
[TBL] [Abstract][Full Text] [Related]
13. Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy.
Cheng S; Han Z; Dai D; Li F; Zhang X; Lu M; Lu Z; Wang X; Zhou J; Li J; Guo X; Song P; Qiu C; Shen W; Zhang Q; Zhu N; Wang X; Tan Y; Kou Y; Yin X; Shen L; Peng Z
Cell Rep Med; 2024 Jan; 5(1):101355. PubMed ID: 38194971
[TBL] [Abstract][Full Text] [Related]
14. An oncogene regulating chromatin favors response to immunotherapy: Oncogene CHAF1A and immunotherapy outcomes.
Ying L; Hu Z; Lu Y; Tao Q; Xiong F; Shu Y; Yang Y; Qiao X; Peng C; Jiang Y; Han M; Xu M; Li X; Wang D
Oncoimmunology; 2024; 13(1):2303195. PubMed ID: 38235318
[TBL] [Abstract][Full Text] [Related]
15. Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM; Chadwick JA; Owen RP; White MJ; Kaplinsky J; Peneva I; Frangou A; Xie PF; Chang J; Roth A; Amess B; James SA; Rei M; Fuchs HS; McCann KJ; Omiyale AO; Jacobs BA; Lord SR; Norris-Bulpitt S; Dobbie ST; Griffiths L; Ramirez KA; Ricciardi T; Macri MJ; Ryan A; Venhaus RR; Van den Eynde BJ; Karydis I; Schuster-Böckler B; Middleton MR; Lu X;
Cancer Cell; 2023 Jul; 41(7):1222-1241.e7. PubMed ID: 37433281
[TBL] [Abstract][Full Text] [Related]
16. Effector Function Characteristics of Exhausted CD8+ T-cell in Microsatellite Stable and Unstable Gastric Cancer.
Han DS; Kwak Y; Lee S; Nam SK; Kong SH; Park DJ; Lee HJ; Kwon NJ; Lee HS; Yang HK
Cancer Res Treat; 2024 Apr; ():. PubMed ID: 38637967
[TBL] [Abstract][Full Text] [Related]
17. Notch activation defines immune-suppressive subsets of ccRCCs with unfavorable benefits from immunotherapy over VEGFR/mTOR inhibitors.
Han S; Xu Y; Chen D; Yang F; Wang M; Zhou Q; Wang G; Li L; Xu C; Wang W; Cai S; Xing N
iScience; 2024 Jan; 27(1):108290. PubMed ID: 38179060
[TBL] [Abstract][Full Text] [Related]
18. Immune characteristics of dedifferentiated retroperitoneal liposarcomas and the reliability of regional samples in evaluating their tumor immune microenvironments.
Zhou C; Li M; Ren Y; Miao F; Wang Y; Wu T; Gou X; Li W
World J Surg Oncol; 2024 Jan; 22(1):25. PubMed ID: 38254190
[TBL] [Abstract][Full Text] [Related]
19. Controversies in upper GI oncology: MSI-H in gastroesophageal adenocarcinoma.
Petrillo A; Derks S; Smyth EC
ESMO Open; 2024 Feb; 9(2):102229. PubMed ID: 38244348
[No Abstract] [Full Text] [Related]
20. Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review.
Tang L; Xu H; Wu T; Wu W; Lu Y; Gu J; Wang X; Zhou M; Chen Q; Sun X; Cai H
Discov Oncol; 2024 Apr; 15(1):111. PubMed ID: 38602556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
